瑞舒伐他汀治疗慢阻肺合并肺动脉高压的临床观察及机制研究

Effects of rosuvastatin on patients with chronic obstructive pulmonary disease combined with pulmonary hypertension

目的观察瑞舒伐他汀治疗慢性阻塞性肺疾病(COPD)合并肺动脉高压(PH)患者的临床价值并分析其可能的作用机制。方法选择稳定期COPD合并PH患者60例,随机分为瑞舒伐他汀治疗组(30例)和对照组(30例)。比较治疗后两组血清中半乳糖凝集素-3(Gal-3)、白介素-6(IL-6)水平及相关临床指标。结果瑞舒伐他汀治疗3个月后,治疗组血清Gal-3,IL-6,PAPs,PAPm较同组治疗前及对照组治疗后均有降低(P<0.05),6MWD较同组治疗前及对照组治疗后均有升高(P<0.05)。结论瑞舒伐他汀能降低COPD合并PAH患者肺动脉压力,运动耐力,其机制可能与其抑制炎症反应有关。

Objectives To explore the clinical efficacy of rosuvastatin in treatment of patients with chronic obstructive pulmonary disease （COPD） combined with pulmonary hypertension （PH） and its mechanism. Methods 60 patients with stable COPD combined with PH were enrolled in this study. Patients were randomly divided into rosuvastatin group（ n = 30）and control group（ n = 30）. The changes of mean pulmonary arterial pressure （PAPm）, pulmonary arterial systolic pressure （PAPs）, 6-minute walking distance （ 6MWD）, the plasma levels of Galectin-3 （ Gal-3 ）, Interleukin-6 （ IL-6 ） were measured after treatment. Results The levels of IL- 6, Gal-3. PAPs and PAPm were significantly lower in rosuvastatin group than in control group after 3month treatment, and the 6MWD was significantly higher（ P 〈 0. 05 ）. Conclusions Rosuvastatin can obviously reduce PAPs, PAPm and improve exercise tolerance of COPD patients combined with PH,which may be caused by rosuvastatin inhibiting the inflammatory reaction.